Skye Bioscience Inc.（简称“Skye”）近日披露了其创新药物Nimacimab与司美格鲁肽（Semaglutide）联合用药的Cbeyond二期a阶段扩展研究的中期分析数据，结果显示疗效积极。
这项扩展研究旨在评估Nimacimab与司美格鲁肽联合治疗方案在特定患者群体中的长期安全性与有效性。中期数据表明，联合用药在关键疗效指标上表现出显著改善，且安全性和耐受性良好，未出现新的不良反应信号。
研究结果的积极进展为Nimacimab的后续临床开发提供了有力支持，也为相关疾病领域的治疗带来了新的潜在选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.